Lovastatin improves neurological outcome after nucleus basalis magnocellularis lesion in rats

Neuroscience

Volumn 167, Issue 3, 2010, Pages 954-963

  Zhao, Z ^a   Zhao, S ^b   Xu, N ^c   Yu, C ^d   Guan, S ^a   Liu, X ^c   Huang, L ^d   Liao, W ^d   Jia, W ^b,e  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b PepMetric and Pegasus Pharmaceuticals Group Inc Unit 110 116   (Canada)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

^d CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Lovastatin; Morris Water Maze; Muscarinic NMDA receptor; Neuroprotection; Nucleus basalis magnocellularis; Signaling pathway

Indexed keywords

CHOLINE ACETYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBOTENIC ACID; MEVINOLIN; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN KINASE B; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN DAMAGE; CELL LOSS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENZYME ACTIVITY; MALE; NERVE CELL; NEUROPROTECTION; NONHUMAN; NUCLEUS BASALIS MAGNOCELLULARIS LESION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

ACETYLCHOLINE; ALZHEIMER DISEASE; ANIMALS; BASAL NUCLEUS OF MEYNERT; BINDING, COMPETITIVE; CEREBRAL CORTEX; CHOLINE O-ACETYLTRANSFERASE; DENERVATION; DISEASE MODELS, ANIMAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IBOTENIC ACID; LOVASTATIN; MALE; NEUROTOXINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MUSCARINIC; RECEPTORS, N-METHYL-D-ASPARTATE; RECOVERY OF FUNCTION; TREATMENT OUTCOME;

EID: 77951297881     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.02.054     Document Type: Article

References (60)

1. Bardeleben R., Kaina B., Fritz G. Ultraviolet light-induced apoptotic death is impaired by the HMG-CoA reductase inhibitor lovastatin. Biochem Biophys Res Commun 2003, 307:401-407.
2. Bois T.M., Newell K.A., Han M., Deng C., Huang X.F. Perinatal PCP treatment alters the developmental expression of prefrontal and hippocampal muscarinic receptors. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:37-40.
3. Botti R.E., Triscari J., Pan H.Y., Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 1991, 14:256-261.
4. Burke J.P., Watson R.W., Murphy M., Docherty N.G., Coffey J.C., O'Connell P.R. Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor beta1-mediated activation of intestinal fibroblasts. Br J Surg 2009, 96:541-551.
5. Caccamo A., Fisher A., LaFerla F.M. M1 agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr Alzheimer Res 2009, 6:112-117.
6. Cerezo-Guisado M.I., Alvarez-Barrientos A., Argent R., García-Marín L.J., Bragado M.J., Lorenzo M.J. c-Jun N-terminal protein kinase signalling pathway mediates lovastatin-induced rat brain neuroblast apoptosis. Biochim Biophys Acta 2007, 1771:164-176.
7. Cerezo-Guisado M.I., García-Román N., García-Marín L.J., Alvarez-Barrientos A., Bragado M.J., Lorenzo M.J. Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts. Biochem J 2007, 401:175-183.
8. Chen B., Liao W.Q., Xu N., Xu H., Wen J.Y., Yu C.A., Liu X.Y., Li C.L., Zhao S.M., Campbell W. Adiponectin protects against cerebral ischemia-reperfusion injury through anti-inflammatory action. Brain Res 2009, 1273:129-137.
9. Chen G., Zhang S., Shi J., Ai J., Qi M., Hang C. Simvastatin reduces secondary brain injury caused by cortical contusion in rats: possible involvement of TLR4/NF-kappaB pathway. Exp Neurol 2009, 216:398-406.
10. Chen L., Haught W.H., Yang B., Saldeen T.G., Parathasarathy S., Mehta J.L. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997, 30:569-575.
11. Contestabile A., Ciani E., Contestabile A. The place of choline acetyltransferase activity measurement in the "cholinergic hypothesis" of neurodegenerative diseases. Neurochem Res 2008, 33:318-327.
12. Davignon J., Mabile L. Mechanisms of action of statins and their pleiotropic effects. Ann Endocrinol (Paris) 2001, 62:101-112.
13. Dembowski E., Davidson M.H. A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev 2009, 29:2-12.
14. Dolga A.M., Nijholt I.M., Ostroveanu A., Ten Bosch Q., Luiten P.G., Eisel U.L. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J Alzheimers Dis 2008, 13:111-122.
15. Evans B.A., Evans J.E., Baker S.P., Kane K., Swearer J., Hinerfeld D., Caselli R., Rogaeva E., George-Hyslop P., Moonis M., Pollen D.A. Long-term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease. Dement Geriatr Cogn Disord 2009, 27:519-524.
16. Fonnum F. A rapid radiochemical method for the determination of choline acetyltransferase. J Neurochem 1975, 24:407-409.
17. Fujii T., Masuyama K., Kawashima K. Simvastatin regulates non-neuronal cholinergic activity in T lymphocytes via CD11a-mediated pathways. J Neuroimmunol 2006, 179:101-107.
18. Fujii T., Takada-Takatori Y., Kawashima K. Roles played by lymphocyte function-associated antigen-1 in the regulation of lymphocytic cholinergic activity. Life Sci 2007, 80:2320-2324.
19. Fujii T., Takada-Takatori Y., Kawashima K. Basic and clinical aspects of non-neuronal acetylcholine: expression of an independent, non-neuronal cholinergic system in lymphocytes and its clinical significance in immunotherapy. J Pharmacol Sci 2008, 106:186-192.
20. Gluhovschi G., Gluhovschi C., Bob F., Velciov S., Trandafirescu V., Petrica L., Bozdog G. Multiorgan-protective actions of blockers of the renin-angiotensin system, statins and erythropoietin: common pleiotropic effects in reno-, cardio- and neuroprotection. Acta Clin Belg 2008, 63:152-169.
21. Gomis M., Ois A., Rodríguez-Campello A., Cuadrado-Godia E., Jiménez-Conde J., Subirana I., Dávalos A., Roquer J. Outcome of intracerebral haemorrhage patients pre-treated with statins. Eur J Neurol 2009, 2009, [Epub ahead of print].
22. Guillot F., Misslin P., Lemaire M. Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods. J Cardiovasc Pharmacol 1993, 21:339-346.
23. Haendeler J., Hoffmann J., Zeiher A.M., Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation 2004, 110:856-861.
24. Handattu S.P., Garber D.W., Monroe C.E., van Groen T., Kadish I., Nayyar G., Cao D., Palgunachari M.N., Li L., Anantharamaiah G.M. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol Dis 2009, 34:525-534.
25. Ho N.F., Han S.P., Dawe G.S. Effect of voluntary running on adult hippocampal neurogenesis in cholinergic lesioned mice. BMC Neurosci 2009, 10:57.
26. Jiang J.L., Wang S., Li N.S., Zhang X.H., Deng H.W., Li Y.J. The inhibitory effect of simvastatin on the ADMA-induced inflammatory reaction is mediated by MAPK pathways in endothelial cells. Biochem Cell Biol 2007, 85:66-77.
27. Kandiah N., Feldman H.H. Therapeutic potential of statins in Alzheimer's disease. J Neurol Sci 2009, 283:230-234.
28. Kita T., Brown M.S., Goldstein J.L. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with Mevinolin, a competitive inhibitor of the reductase. J Clin Invest 1980, 66:1094-1100.
29. Li W.D., Cui Y.J., Kushner S.A., Brown R., Jentsch D., Frankland P.W., Cannon T.D., Silva A.J. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 2005, 21:1961-1967.
30. Lu D., Qu C., Goussev A., Jiang H., Lu C., Schallert T., Mahmood A., Chen J., Li Y., Chopp M. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma 2007, 24:1132-1146.
31. Lütjohann D., von Bergmann K. 24S-hydroxycholesterol: a marker of brain cholesterol metabolism. Pharmacopsychiatry 2003, 36(Suppl 2):S102-S106.
32. Matsuzawa A., Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta 2008, 1780:1325-1336.
33. Meyer-Ter-Vehn T., Katzenberger B., Han H., Grehn F., Schlunck G. Lovastatin inhibits TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest Ophthalmol Vis Sci 2008, 49:3955-3960.
34. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994, 12:529-540.
35. Mufson E.J., Counts S.E., Perez S.E., Ginsberg S.D. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother 2008, 8:1703-1718.
36. Paintlia A.S., Paintlia M.K., Singh I., Skoff R.B., Singh A.K. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 2009, 57:182-193.
37. +/- mouse hippocampus. J Neurosci Res 2009, 87:3107-3119.
38. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic Press, Sydney. 2nd ed.
39. Qu C., Lu D., Goussev A., Schallert T., Mahmood A., Chopp M. Effect of atorvastatin on spatial memory, neuronal survival, and vascular density in female rats after traumatic brain injury. J Neurosurg 2005, 103:695-701.
40. Reiss A.B., Wirkowski E. Statins in neurological disorders: mechanisms and therapeutic value. Scientific World J 2009, 9:1242-1259.
41. Riedel G., Platt B., Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res 2003, 140:1-47.
42. Rupérez M., Rodrigues-Díez R., Blanco-Colio L.M., Sánchez-López E., Rodríguez-Vita J., Esteban V., Carvajal G., Plaza J.J., Egido J., Ruiz-Ortega M. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension 2007, 50:37-83.
43. Saheki A., Terasaki T., Tamai I., Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors. Pharm Res 1994, 11:305-311.
44. Shimizu E., Tang Y.P., Rampon C., Tsien J.Z. NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation. Science 2000, 290:1170-1174.
45. Sironi L., Banfi C., Brioschi M., Gelosa P., Guerrini U., Nobili E., Gianella A., Paoletti R., Tremoli E., Cimino M. Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment. Neurobiol Dis 2006, 22:445-451.
46. Song C.Y., Kim B.C., Lee H.S. Lovastatin inhibits oxidized low-density lipoprotein-induced plasminogen activator inhibitor and transforming growth factor-beta1 expression via a decrease in Ras/extracellular signal-regulated kinase activity in mesangial cells. Transl Res 2008, 151:27-35.
47. Tobin G., Giglio D., Lundgren O. Muscarinic receptor subtypes in the alimentary tract. J Physiol Pharmacol 2009, 60:3-21.
48. Tsien J.Z., Huerta P.T., Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell 1996, 87:1327-1338.
49. Wang H., Lynch J.R., Song P., Yang H.J., Yates R.B., Mace B., Warner D.S., Guyton J.R., Laskowitz D.T. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol 2007, 206:59-69.
50. Wang Q., Zengin A., Ying W., Newell K.A., Wang P., Yeo W., Wong P.T., Yenari M.A., Huang X.F. Chronic treatment with simvastatin upregulates muscarinic M1/4 receptor binding in the rat brain. Neuroscience 2008, 154:1100-1106.
51. Wang Q., Zengin A., Deng C., Li Y., Newell K.A., Yang G.Y., Lu Y., Wilder-Smith E.P., Zhao H., Huang X.F. High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: the association with the up-regulation of NMDA receptor binding in the rat brain. Exp Neurol 2009, 216:132-138.
52. Weitberg A.B. The antioxidant effect of lovastatin on phagocyte-induced DNA damage: implications for cancer prevention. J Exp Clin Cancer Res 2007, 26:583-586.
53. Wu H., Lu D., Jiang H., Xiong Y., Qu C., Li B., Mahmood A., Zhou D., Chopp M. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma 2008, 25:130-139.
54. Xiu J., Nordberg A., Shan K.R., Yu W.F., Olsson J.M., Nordman T., Mousavi M., Guan Z.Z. Lovastatin stimulates up-regulation of alpha7 nicotinic receptors in cultured neurons without cholesterol dependency, a mechanism involving production of the alpha-form of secreted amyloid precursor protein. J Neurosci Res 2005, 82:531-541.
55. Yamashita M., Otsuka F., Mukai T., Otani H., Inagaki K., Miyoshi T., Goto J., Yamamura M., Makino H. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. J Endocrinol 2008, 196:601-613.
56. Yamin G. NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. J Neurosci Res 2009, 87:1729-1736.
57. Yashiro K., Philpot B.D. Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology 2008, 55:1081-1094.
58. Yoneda Y., Ogita K. Labeling of NMDA receptor channels by 3H-MK801 in brain synaptic membranes treated with TritonX-100. Brain Res 1989, 499:305-314.
59. Zhao S.M., Liao W.Q., Xu N., Xu H., Yu C.A., Liu X.Y., Li C.L. Polar metabolite of cholesterol induces rat cognitive dysfunctions. Neuroscience 2009, 164:398-403.
60. Zhou Q., Kummerow A.F. Antioxidative effects of lovastatin in cultured human endothelial cells. J Nutr Biochem 2002, 13:200-208.